Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2017

Listed Company Name:Eisai Co., Ltd.
Representative:Haruo Naito
Representative Corporate
Officer and CEO
Securities Code:4523
Stock Exchange Listings:First Section of the Tokyo
Stock Exchange
Inquiries:Sayoko Sasaki
Vice President, Corporate Affairs
Phone +81-3-3817-5120

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2017 (April 1, 2016 to March 31, 2017) previously announced on May 13, 2016, as follows:

1. Revised full-year consolidated financial forecasts for the fiscal year ending March 31, 2017

(April 1, 2016 to March 31, 2017)

(Unit: Millions of yen, unless otherwise noted.)

*You can scroll to the left or right here

  Revenue Operating
Profit before
income taxes
Profit for
the period
Profit for
the period
attributable to owners of
the parent
per share
Previously announced forecast(A)(May 13, 2016) 580,000 53,700 52,200 32,400 29,200 102.12 yen
Currently revised forecast(B) 548,000 60,000 58,800 44,000 41,300 144.43 yen
Change in amount (B - A) -32,000 6,300 6,600 11,600 12,100  
Percentage of change (%) -5.5% 11.7% 12.6% 35.8% 41.4%  
(Reference) Business results for the fiscal year ended March 31, 2016 547,922 51,935 50,473 55,045 54,933 192.23 yen

(Assumptions for the third and fourth quarter of FY2016: USD 1 = JPY 101, EUR 1 = JPY 113, GBP 1 = JPY 131,CNY 1 = JPY 15.0)

2. Reason for revision of the consolidated financial forecasts

Despite growth in all regions as well as growth of global brands Halaven, Lenvima and Fycompa on a local currency basis, revenue is forecasted to be ¥548,000 million (about the same year on year) due to the impact of revisions to the assumed exchange rates based on recent foreign exchange trends.

Operating profit is forecasted to increase by ¥6,300 million from the previous forecast to ¥60,000 million (up 15.5% year on year). While Eisai continues to make proactive investment in priority research and development projects, positive contributions are anticipated such as growth in global brands, improved performance and efficiency in operations as well as one-off income following the acquisition of EA Pharma shares (gain from a bargain purchase).

As a result, profit for the period attributable to owners of the parent is forecast to be ¥41,300 million, ¥12,100 million higher (down 24.8% year on year) than the previous forecast.

Furthermore, Eisai intends to set the dividend for the period (second six-month period ending March 31, 2017) at ¥80 per share, with the forecast for the total dividend for the year remaining unchanged at ¥150 per share (same amount as the previous fiscal year).

  • *
    Please note that actual business results may change due to several factors since the above-mentioned forecasts were made based on information available as of October 31, 2016.